Pharmacogenetics: A Tool for Identifying Genetic Factors in Drug Dependence and Response to Treatment

Por Mroziewicz, Margaret, Tyndale, Rachel F.
Publicado em 2010

Cytochromes P450 in the brain: Emerging evidence for biological significance

Por Ferguson, Charmaine S., Tyndale, Rachel F.
Publicado em 2011

2011 CCNP Heinz Lehmann Award paper: Cytochrome P450–mediated drug metabolism in the brain

Por Miksys, Sharon, Tyndale, Rachel F.
Publicado em 2013

Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition

Por Miksys, Sharon, Tyndale, Rachel F
Publicado no Neuropsychopharmacology (2008)

Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells

Por Mann, Amandeep, Tyndale, Rachel F.
Publicado no Eur J Neurosci (2010)

Drug-metabolizing cytochrome P450s in the brain

Por Miksys, Sharon L., Tyndale, Rachel F.
Publicado em 2002

Drug Metabolism within the Brain Changes Drug Response: Selective Manipulation of Brain CYP2B Alters Propofol Effects

Por Khokhar, Jibran Y, Tyndale, Rachel F
Publicado em 2011

Pharmacogenetic Optimization of Smoking Cessation Treatment

Por Chenoweth, Meghan J., Tyndale, Rachel F.
Publicado no Trends Pharmacol Sci (2016)

Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine-Metabolizing Enzymes

Por Ray, Riju, Tyndale, Rachel F., Lerman, Caryn
Publicado em 2009

Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine

Por McMillan, Douglas M, Tyndale, Rachel F
Publicado no Neuropsychopharmacology (2015)

Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein

Por Lee, Anna M, Miksys, Sharon, Tyndale, Rachel F
Publicado em 2006

CYP2A6 genotyping methods and strategies using real-time and endpoint PCR platforms

Por Wassenaar, Catherine A., Zhou, Qian, Tyndale, Rachel F.
Publicado no Pharmacogenomics (2015)

Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course

Por Yue, Jiang, Miksys, Sharon, Hoffmann, Ewa, Tyndale, Rachel F.
Publicado em 2008

Socioeconomic and drug use determinants of smoking status in a Canadian urban adult population of black African descent

Por Mwenifumbo, Jill C., Sellers, Edward M., Tyndale, Rachel F.
Publicado em 2008

Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake

Por Yue, Jiang, Khokhar, Jibran, Miksys, Sharon, Tyndale, Rachel F.
Publicado no Eur J Pharmacol (2009)

First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo

Por Zhou, Kaidi, Khokhar, Jibran Y., Zhao, Bin, Tyndale, Rachel F.
Publicado em 2013

EFFECT OF FOOD TRAINING AND TRAINING DOSE ON NICOTINE SELF-ADMINISTRATION IN RATS

Por Garcia, Kristine L.P., Lê, Anh Dzung, Tyndale, Rachel F.
Publicado em 2014

BRAIN CYP2B INDUCTION CAN DECREASE NICOTINE LEVELS IN THE BRAIN

Por Garcia, Kristine L.P., Lê, Anh Dzung, Tyndale, Rachel F.
Publicado no Addict Biol (2016)

Hepatic CYP2A6 levels and nicotine metabolism: Impact of genetic, physiologic, environmental, and epigenetic factors

Por Al Koudsi, Nael, Hoffmann, Ewa B., Assadzadeh, Abbas, Tyndale, Rachel F.
Publicado no Eur J Clin Pharmacol (2009)

Effect of UGT2B10, UGT2B17, FMO3, and OCT2 Genetic Variation on Nicotine and Cotinine Pharmacokinetics and Smoking in African Americans

Por Taghavi, Taraneh, St. Helen, Gideon, Benowitz, Neal L., Tyndale, Rachel F.
Publicado no Pharmacogenet Genomics (2017)